Correction: median 42 not 24 days."On August 3, 2012, the Food and Drug Administration approved a new cancer drug called Zaltrap as a safe and effective treatment for patients with advanced colon cancer. The approval was based on a large-scale clinical trial that showed that Zaltrap, given in combination with three previously approved drugs to patients who had failed initial therapy, extended median overall survival by 42 days. "

October 2013 New York Magazine: "The Cost of Living. New drugs could extend cancer patients’ lives—by days at a cost of thousands and thousands of dollars, prompting some doctors to refuse to use them."

http://nymag.com/news/features/cancer-drugs-2013-10/